Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0FWNJ)

• Drug Name: 9-hydroxyoctadecadienoic acid Drug Info
• Synonyms: (9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic; 9(S)-HODE

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5312830
  ChEBI ID: CHEBI:34496
  CAS Number: CAS 73543-67-6
  TTD Drug ID: DM0FWNJ

Molecule-Related Drug Atlas

Drug(s) Targeting Peroxisome proliferator-activated receptor gamma (PPAR-gamma)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[5]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[6]
Lobeglitazone	DMHY3IP	Type-2 diabetes	5A11	Approved	[7]
Rosiglitazone XR	DMT45MU	Type-2 diabetes	5A11	Approved	[8]
Thiazolidinedione	DMC1NBW	Alzheimer disease	8A20	Approved	[6]
Glitazone	DMDN4A1	N. A.	N. A.	Phase 4	[9]
MURAGLITAZAR	DMG3NFZ	N. A.	N. A.	Phase 3	[10]
Rivoglitazone	DMBY31K	Ocular inflammation	9C61.24	Phase 3	[11]
Balaglitazone	DMXBHR6	Type-1 diabetes	5A10	Phase 3	[12]
Ragaglitazar	DMFSHEM	Type-1 diabetes	5A10	Phase 3	[13]

Drug(s) Affected By Large ribosomal subunit protein uL10 (RPLP0)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[14]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[15]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[18]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[19]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[21]
Napabucasin	DMDZ6Q3	Colorectal cancer	2B91.Z	Phase 3	[22]
Geldanamycin	DMS7TC5	Kidney cancer	2C90.0	Discontinued in Phase 2	[23]

Drug(s) Affected By Heat shock protein HSP 90-beta (HSP90AB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[24]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[25]
Selenium	DM25CGV	N. A.	N. A.	Approved	[26]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[27]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[28]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[29]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[30]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[32]

Drug(s) Affected By Protein 4.1 (EPB41)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[15]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[32]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[34]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[35]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[36]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[37]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[38]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[39]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[40]

Drug(s) Affected By Proliferating cell nuclear antigen (PCNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[41]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[42]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[43]
Selenium	DM25CGV	N. A.	N. A.	Approved	[44]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[45]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[46]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[47]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[48]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[49]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[50]

Drug(s) Affected By Keratin, type I cytoskeletal 9 (KRT9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[51]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[53]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[54]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[55]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[56]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[57]

Drug(s) Affected By Caspase-5 (CASP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[58]
Sanguinarine	DMDINFS	Dental plaque	DA08.4	Approved	[58]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[59]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[60]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[61]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[18]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[62]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[56]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[62]
CHLORANIL	DMCHGF1	Discovery agent	N.A.	Investigative	[63]

Drug(s) Affected By Actin, cytoplasmic 1 (ACTB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[64]
Selenium	DM25CGV	N. A.	N. A.	Approved	[26]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[27]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[15]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[66]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[65]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]

Drug(s) Affected By Heterogeneous nuclear ribonucleoprotein K (HNRNPK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[68]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[69]
Haloperidol	DM96SE0	Delirium		Approved	[70]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[72]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[20]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[69]

Drug(s) Affected By Actin, cytoplasmic 2 (ACTG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[26]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[73]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[71]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[18]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[76]

Drug(s) Affected By Protein BTG2 (BTG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[77]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[78]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[30]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[79]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[80]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[81]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[82]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[83]

Drug(s) Affected By Protein SET (SET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[15]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[85]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[87]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[19]

Drug(s) Affected By Plasminogen-like protein B (PLGLB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[18]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[88]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[89]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[38]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[90]

Drug(s) Affected By Chromobox protein homolog 3 (CBX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[43]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[33]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[92]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[91]
Bortezomib	DMNO38U	Leukemia		Approved	[93]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[18]

Drug(s) Affected By Leucine-rich repeat-containing protein 49 (LRRC49)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[32]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[94]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[95]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[96]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[39]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[97]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[90]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
G2 accumulation protein (GPR132)	TTNBW4F	GP132_HUMAN	Agonist	[2]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	TTZMAO3	PPARG_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Actin, cytoplasmic 1 (ACTB)	OT1MCP2F	ACTB_HUMAN	Gene/Protein Processing	[4]
Actin, cytoplasmic 2 (ACTG1)	OTH4V7VQ	ACTG_HUMAN	Gene/Protein Processing	[4]
Caspase-5 (CASP5)	OT0F2THD	CASP5_HUMAN	Gene/Protein Processing	[4]
Chromobox protein homolog 3 (CBX3)	OTOP9RLD	CBX3_HUMAN	Gene/Protein Processing	[4]
Heat shock protein HSP 90-beta (HSP90AB1)	OTR69EG7	HS90B_HUMAN	Gene/Protein Processing	[4]
Heterogeneous nuclear ribonucleoprotein K (HNRNPK)	OTNPRM8U	HNRPK_HUMAN	Gene/Protein Processing	[4]
Keratin, type I cytoskeletal 9 (KRT9)	OTA10UCH	K1C9_HUMAN	Gene/Protein Processing	[4]
Large ribosomal subunit protein uL10 (RPLP0)	OT3XKD6Y	RLA0_HUMAN	Gene/Protein Processing	[4]
Leucine-rich repeat-containing protein 49 (LRRC49)	OT9SOV66	LRC49_HUMAN	Gene/Protein Processing	[4]
Plasminogen-like protein B (PLGLB2)	OTFG76E9	PLGB_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5567).
• [2] Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J Biol Chem. 2005 Dec 9;280(49):40676-83.
• [3] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [4] A proteomic analysis of acute leukemia cells treated with 9-hydroxyoctadecadienoic acid. Lipids Health Dis. 2016 Nov 10;15(1):192. doi: 10.1186/s12944-016-0359-4.
• [5] Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
• [6] Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
• [7] Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
• [8] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [9] Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
• [10] Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
• [11] A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
• [12] Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
• [13] Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
• [14] Dephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicity. Toxicol Lett. 2006 Oct 25;166(3):189-99. doi: 10.1016/j.toxlet.2006.07.303. Epub 2006 Aug 8.
• [15] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [16] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [17] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [18] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [19] Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics. 2009 Apr;9(7):1952-66. doi: 10.1002/pmic.200701089.
• [20] Arsenic modulates posttranslational S-nitrosylation and translational proteome in keratinocytes. ScientificWorldJournal. 2014;2014:360153.
• [21] Identification of estrogen-induced genes downregulated by AhR agonists in MCF-7 breast cancer cells using suppression subtractive hybridization. Gene. 2001 Jan 10;262(1-2):207-14. doi: 10.1016/s0378-1119(00)00530-8.
• [22] Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi: 10.1073/pnas.1424171112. Epub 2015 Jan 20.
• [23] RNA-binding proteins and heat-shock protein 90 are constituents of the cytoplasmic capping enzyme interactome. J Biol Chem. 2018 Oct 26;293(43):16596-16607. doi: 10.1074/jbc.RA118.004973. Epub 2018 Aug 30.
• [24] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [25] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [26] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [27] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [28] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [29] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [30] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [31] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [32] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [33] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [34] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [35] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [36] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [37] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [38] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [39] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [40] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [41] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [42] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [43] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [44] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [45] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [46] Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol. 2021 Mar 15;415:115450. doi: 10.1016/j.taap.2021.115450. Epub 2021 Feb 9.
• [47] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [48] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [49] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [50] Epinephrine facilitates the growth of T cell lymphoma by altering cell proliferation, apoptosis, and glucose metabolism. Chem Biol Interact. 2023 Jan 5;369:110278. doi: 10.1016/j.cbi.2022.110278. Epub 2022 Nov 22.
• [51] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [52] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [53] Identification of potential biomarkers for predicting acute dermal irritation by proteomic analysis. J Appl Toxicol. 2011 Nov;31(8):762-72.
• [54] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [55] Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and Visualization of Multi-Omics Data. Toxicol Sci. 2018 May 1;163(1):182-195. doi: 10.1093/toxsci/kfy012.
• [56] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [57] Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.
• [58] Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.
• [59] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [60] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [61] Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
• [62] Gene alterations of ovarian cancer cells expressing estrogen receptors by estrogen and bisphenol a using microarray analysis. Lab Anim Res. 2011 Jun;27(2):99-107. doi: 10.5625/lar.2011.27.2.99. Epub 2011 Jun 22.
• [63] Atypical Gasdermin D and Mixed Lineage Kinase Domain-like Protein Leakage Aggravates Tetrachlorobenzoquinone-Induced Nod-like Receptor Protein 3 Inflammasome Activation. Chem Res Toxicol. 2018 Dec 17;31(12):1418-1425. doi: 10.1021/acs.chemrestox.8b00306. Epub 2018 Nov 9.
• [64] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [65] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [66] Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002 Aug 9;449(3):197-205.
• [67] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [68] Chronic cyclophosphamide exposure alters the profile of rat sperm nuclear matrix proteins. Biol Reprod. 2007 Aug;77(2):303-11. doi: 10.1095/biolreprod.107.060244. Epub 2007 May 2.
• [69] Protein kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Exp Cell Res. 2009 Nov 15;315(19):3250-8. doi: 10.1016/j.yexcr.2009.09.005. Epub 2009 Sep 10.
• [70] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [71] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [72] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [73] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [74] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [75] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [76] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [77] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [78] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [79] Role of DNA Repair Pathways in Response to Zidovudine-induced DNA Damage in Immortalized Human Liver THLE2 Cells. Int J Biomed Sci. 2013 Mar;9(1):18-25.
• [80] Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.
• [81] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [82] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [83] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [84] Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol. 2003 May;85(1):1-8. doi: 10.1016/s0960-0760(03)00142-0.
• [85] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [86] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [87] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [88] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [89] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [90] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [91] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [92] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [93] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [94] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [95] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [96] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [97] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.